To include your compound in the COVID-19 Resource Center, submit it here.

ABX464 reduces HIV reservoirs in Ph IIa trial

Abivax S.A.S. (Euronext:ABVX) said ABX464 for 28 days reduced HIV reservoirs as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs) in the Phase IIa ABX464-004 trial to treat

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE